Leadership

The company's team

A collaboration of consultants and professionals — bringing together expertise spanning veterinary pharmaceuticals, the medical industry, law and business.

At Byrock Technologies, our diverse team brings together expertise from various fields to create and deliver innovative solutions in the equine pharmaceutical industry. Our flagship product, PTP-102, represents a breakthrough in veterinary medicine.

With a wealth of experience spanning veterinary pharmaceuticals, the medical industry, law and business, our team is equipped to manage every stage of the product lifecycle, from laboratory research to market launch.

5 leadership profiles

Abstract equine biomechanical anatomical study

Fig 3.0 — Biomechanical Study

Discovery of the PTP-102 mechanism · 53 patents

Founder

Patrick T. Prendergast

Patrick is the Founder of Byrock Technologies. As a result of extensive research, Patrick discovered a treatment for equine laminitis. Patrick holds 53 patents and has a proven track record of bringing his patents to market, some of which are generating significant royalties. PTP-102 is a significant breakthrough in the treatment of laminitis. The breakthrough was achieved by Patrick taking a fresh look at all the available research in this area. Patrick's inquisitiveness and passion are ingrained in Byrock's mission.

Portrait of Dr. Daniel Shanahan-Prendergast

Clinical research coordination · New York office

Research Coordinator

Dr. Daniel Shanahan-Prendergast

Daniel is a Research Coordinator at Byrock Technologies. He has extensive experience in medical research. He graduated as a Medical Doctor (MD) from All Saints University, School of Medicine. Daniel has coordinated and overseen previous equine laminitis studies at the East Tennessee Center for Clinical Research. He currently resides in Brooklyn, NY where he manages the company's New York office. Daniel has 2 patents.

7 laminitis trial projects · IACUC Chair

Clinical Trials Veterinarian

Dr. Julio Prada

Julio graduated as a veterinarian at La Universidad del Zulia in his hometown of Maracaibo, Venezuela. He practiced as a farm animal and equine veterinarian for 2 years. Julio worked for Schering Plough Animal Health before deciding to migrate with his family to US. For the last 8 years he worked at East Tennessee Clinical Research (ETCR) as Director of Animal Care, IACUC Chair and Clinical Trials Veterinarian. At ETCR Dr. Prada led 7 different laminitis projects where dozens of horses were experimentally induced and treated with multiple compounds in attempts to develop a treatment for the disease. Currently Dr. Prada is working on his thesis to complete an MS in Animal Physiology at the University of Tennessee in Knoxville.

Legal counsel · Angel investor

Investor & Legal Advisor

Anthony Joyce

Anthony is the founding partner of Anthony Joyce & Co. Solicitors. He has an LLB Law Degree from the University of London. He is qualified to practice as a Solicitor in Ireland, England and Wales. Anthony is a Chairperson of the Liberties Business Forum, Dublin and a Member of the Institute of Directors. Anthony is an investor in the development of PTP-102. As an angel investor, he brings his expertise, knowledge and industry connections to the management team.

International R&D · Business development

Project Development Coordinator

Cormac Jones

Cormac is the project development coordinator at Byrock Technologies. Fluent in Spanish from his studies at NUIG, Cormac leads international research and development efforts, along with business development strategies at Byrock Technologies. Currently training as a solicitor in Ireland, his early life around horses inspired his passion for advancing equine health solutions.

Building the future of equine health

PTP-102 is advanced by a team combining veterinary, scientific, regulatory and commercial expertise.

Get in touch